Autosomal Dominant Robinow Syndrome 1 (DRS1) — Comprehensive Research Report

1. Disease Information

Overview. Robinow syndrome is a rare, genetically heterogeneous skeletal dysplasia first described in 1969 by Meinhard Robinow, Frederic Silverman, and Hugo Smith, who reported a mother and three children with "mesomelic brachymelia, hemivertebrae, peculiar facies and genital hypoplasia," a constellation they termed a form of dwarfism with fetal facies [Robinow, Silverman & Smith, Am J Dis Child, 1969] (PMC, PMC). Autosomal Dominant Robinow Syndrome 1 (DRS1) is the specific molecular subtype caused by heterozygous pathogenic variants in WNT5A (chromosome 3p14.3) — the original locus in the family Robinow himself described. It is distinguished from the more recently identified dominant subtypes DRS2 (DVL1, 1p36.33) and DRS3 (DVL3, 3q27.1), and from the autosomal recessive forms caused by biallelic ROR2 or NXN variants (OMIM #180700; OMIM #616331; GeneReviews NBK268648).

Key identifiers: - OMIM: #180700 (ROBINOW SYNDROME, AUTOSOMAL DOMINANT 1; DRS1) - Disease Ontology: DOID:0060766 - Orphanet: ORPHA:3107 (Autosomal dominant Robinow syndrome) - Gene: WNT5A (HGNC:12784), chromosome 3p14.3 - MedGen: C4551475 ("Autosomal dominant Robinow syndrome 1") - Related dominant entries: OMIM #616331 (DRS2/DVL1), #616894 (DRS3/DVL3) - Related recessive entries: OMIM #268310 (RRS1/ROR2)

Synonyms: Robinow syndrome, dominant type; Fetal face syndrome; Mesomelic dwarfism, Robinow type; Robinow-Silverman-Smith syndrome (historic).

Evidence basis: Robinow syndrome information is derived overwhelmingly from aggregated, curated disease-level resources (OMIM, GeneReviews, Orphanet) built from an accumulation of published case reports and small case series — the disease is too rare for large EHR-derived cohort data. Fewer than 80 dominant-Robinow-syndrome families have been reported across all three dominant genes combined (GeneReviews NBK268648); Orphanet estimates prevalence <1/1,000,000 for the dominant form with roughly 100 cases reported in the literature (Orphanet ORPHA:3107).

Suggested MONDO/HPO grounding: MONDO term for the WNT5A subtype should map to OMIM:180700/DOID:0060766/ORPHA:3107.

2. Etiology

Disease Causal Factor

DRS1 is caused by heterozygous, typically de novo, missense variants (and in-frame duplications/deletion-duplications) in WNT5A, which encodes the non-canonical Wnt ligand WNT5A (Person et al. 2010, Dev Dyn, PMID:19918918). Person et al. identified two distinct missense substitutions of highly conserved cysteine residues in WNT5A — one found in all living affected members of Robinow's original family, another in a second unrelated proband — both of which caused decreased WNT5A activity in zebrafish and Xenopus functional assays.

Genetic Risk Factors

• Causal variants: Missense substitutions affecting conserved cysteines and other residues clustering on one face of the WNT5A protein (modeled on WNT8 homology), thought to disrupt protein-protein interactions within the Wnt pathway rather than gross folding (GeneReviews NBK268648).
• The recurrent p.Cys83Ser (C83S) variant is the best-studied WNT5A allele. Its mechanism has been debated — dominant-negative, loss-of-function, or hypomorphic — but recent zebrafish/Xenopus and mouse chondrocyte-orientation work supports a hypomorphic, non-dominant-negative model in which the variant perturbs the spatial gradient of Wnt/PCP signaling rather than simply reducing total signal (Human Molecular Genetics, 2019; Research Square 2025 preprint).
• ~9.5% of clinically diagnosed Robinow syndrome cases overall are attributable to WNT5A missense variants, per cohort sequencing studies (WNT Signaling Perturbations Underlie the Genetic Heterogeneity of Robinow Syndrome, AJHG).
• De novo occurrence: Approximately half of all ADRS cases (across genes) arise de novo; the remainder are inherited from an affected, mildly-expressing parent (GeneReviews NBK268648).

Environmental Risk Factors

None established. This is a monogenic Mendelian disorder with no known environmental, infectious, or lifestyle contributory factors identified in the literature.

Protective Factors

None reported (genetic or environmental) — not applicable to this monogenic dominant disorder.

Gene-Environment Interactions

Not established or investigated; the disorder's severity and penetrance appear driven by variant-specific effects on WNT5A protein function (genotype), not by external modifiers.

3. Phenotypes

Craniofacial ("fetal facies")

• Broad, prominent forehead / frontal bossing — HP:0011220 (Prominent forehead)
• Hypertelorism — HP:0000316
• Prominent, widely spaced eyes — HP:0000488 / HP:0000316
• Short, upturned nose with depressed/wide nasal bridge — HP:0000407 / HP:0000431
• Midface hypoplasia / midface retrusion — HP:0011800
• Broad, triangular mouth — HP:0000175 (Bifid uvula) not applicable; use HP:0002000 (Short columella) / free text
• Macrocephaly (often present prenatally, persisting postnatally) — HP:0000256
• Micrognathia in some — HP:0000347
• Cleft lip/palate (minority) — HP:0000175 / HP:0000202

Dental/Oral

• Malocclusion — HP:0000689
• Dental crowding — HP:0000678
• Hypodontia — HP:0000668
• Delayed eruption of permanent teeth — HP:0000684
• Gingival hypertrophy — HP:0000212
• Bifid/bilobed tongue — HP:0010297

Skeletal

• Short stature, typically ≤ −2 SD in adults — HP:0004322
• Mesomelic limb shortening, predominantly upper limbs (forearms) — HP:0003027
• Brachydactyly — HP:0001156
• Clinodactyly — HP:0030084
• Hemivertebrae — HP:0002937
• Scoliosis — HP:0002650
• Radial head dislocation (minority) — HP:0003083
• Broad thumbs/first toes reported in some subtypes — HP:0011304

Genital/Urogenital

• Males: micropenis / webbed or buried penis — HP:0000054; hypoplastic scrotum — HP:0000047; cryptorchidism — HP:0000028
• Females: hypoplastic clitoris and labia majora — HP:0000053
• Renal anomalies (minority, <25%) — HP:0000077

Cardiac and Other

• Congenital cardiac defects (minority but "a major cause of morbidity and mortality" when present) — HP:0001627
• Nail dysplasia — HP:0008404
• Hearing loss (more classically reported with DVL1/DRS2) — HP:0000365
• Cognitive delay — rare — HP:0001256

Onset/course: Congenital; craniofacial "fetal face" gestalt is most striking in infancy/early childhood and becomes less apparent with age. Fetal ultrasound can detect mesomelic shortening and facial features by ~20 weeks gestation (GeneReviews NBK268648). The disease course is generally stable/non-progressive apart from scoliosis, which can worsen through growth. Severity is variable even within families carrying the same variant.

Frequency data: Cardiac defects, renal anomalies, radial head dislocation, vertebral defects, nail dysplasia, cleft lip/palate, and cognitive delay are each reported in <25% of cases; craniofacial, skeletal, dental, and genital features are near-penetrant/core diagnostic features.

Quality of life: No disease-specific QoL instrument was identified in the literature search; impact is inferred from surgical burden (orthopedic, dental, urogenital, cardiac interventions) and short stature. Cognitive function is typically normal, which is an important prognostic/QoL distinguishing feature versus the more severe recessive (ROR2) form.

4. Genetic/Molecular Information

Causal gene: WNT5A (HGNC:12784; NCBI Gene ID: 7474; Ensembl ENSG00000114251); OMIM gene entry *164975.

Variant classes: Predominantly missense substitutions (notably affecting conserved cysteine residues, e.g., p.Cys83Ser, p.Cys182Arg), plus in-frame duplications and in-frame deletion-duplications clustering on one face of the modeled WNT5A protein structure, implicating disrupted protein-protein interaction surfaces rather than global misfolding (GeneReviews NBK268648; Person et al. 2010, PMID:19918918).

Variant classification (ACMG/ClinVar): Reported WNT5A variants in Robinow syndrome are classified Pathogenic/Likely Pathogenic in ClinVar; sequence analysis detects the great majority of pathogenic variants (large deletions/duplications are not expected to be disease-relevant given the mechanism).

Functional consequence: Debated between loss-of-function, dominant-negative, and hypomorphic mechanisms; current evidence (zebrafish, Xenopus, and mouse Wnt5a-C83S knock-in chondrocyte-polarity studies) favors a hypomorphic, gradient-disrupting model rather than simple haploinsufficiency or classic dominant-negative antagonism (HMG 2019; PMC12776500, 2025). Notably, this contrasts with the DVL1/DVL3-associated forms (DRS2/DRS3), where all identified variants are heterozygous frameshift mutations clustering in the penultimate/ultimate exon (exon 14/15), producing truncated proteins that escape nonsense-mediated decay — consistent with a gain-of-function mechanism distinct from WNT5A's (White et al. 2015, AJHG, PMID:25817016; Roifman et al. 2015, PMID:25817014, osteosclerotic DVL1-Robinow).

Germline origin: All reported DRS1 variants are germline (constitutional), inherited or de novo; no somatic/mosaic Robinow cohort data were identified.

Modifier genes: None formally established for DRS1; phenotypic variability within families with the same WNT5A variant suggests unidentified modifiers or stochastic developmental variation.

Epigenetics: No disease-specific epigenetic (DNA methylation/histone) data identified for WNT5A-Robinow syndrome in the literature searched.

Chromosomal abnormalities: Not a feature — DRS1 is a single-gene point-mutation disorder, not a copy-number/structural disorder.

Suggested HGNC/gene term: hgnc:12784 (WNT5A).

5. Environmental Information

No environmental toxins, occupational exposures, radiation, or infectious agents are established contributors to DRS1 — it is a fully monogenic Mendelian disorder. No lifestyle/behavioral risk-modifying factors (smoking, diet, exercise) are documented in the literature. Not applicable: infectious agents.

6. Mechanism / Pathophysiology

Molecular Pathway

WNT5A is the prototypic ligand for non-canonical Wnt signaling, principally the Wnt/Planar Cell Polarity (Wnt/PCP) pathway, and can also modulate canonical (β-catenin-dependent) Wnt signaling depending on receptor context. WNT5A signals through the receptor tyrosine kinase ROR2 (and related receptors) and downstream through Disheveled (DVL1/DVL3) as an obligate intracellular adaptor, activating small GTPases (RhoA, Rac1, Cdc42) and JNK signaling rather than β-catenin/TCF transcription (GeneReviews NBK268648; Mechanistic studies in Drosophila and chicken, DMM 2023, PMC10120075). Suggested GO term: GO:0035567 (non-canonical Wnt signaling pathway) / GO:0060071 (Wnt signaling pathway, planar cell polarity pathway).

Causal chain: WNT5A ligand (reduced/altered activity due to missense variant) → diminished/dysregulated ROR2-mediated non-canonical Wnt signal transduction → impaired DVL-dependent PCP effector activation (Rho/Rac/JNK) → loss of coordinated, polarized cell behavior in developing tissues (chondrocyte columnar alignment, convergent-extension-like elongation movements) → shortened, disorganized cartilage growth plates and abnormal skeletal elongation (mesomelic limb shortening, short stature) plus disrupted craniofacial and genital morphogenesis.

Cellular Processes

• Chondrocyte planar polarity and columnar organization in growth-plate cartilage is disrupted: WNT5A-C83S-expressing cartilage shows randomly oriented (rather than columnar) chondrocytes and diffuse (rather than polarized) Prickle protein localization, a direct readout of disrupted PCP (Human Molecular Genetics 2019; Research Square/PMC12776500 2025).
• Convergent-extension-like cell movements required for axial elongation and limb bud patterning depend on non-canonical Wnt (Wnt5/Wnt11) signaling in vertebrate models; impaired Wnt5a signaling is analogous to zebrafish pipetail (wnt5) mutant phenotypes affecting gastrulation cell-shape and movement (PMC1299299; general zebrafish CE literature).
• Limb bud initiation, digit patterning, joint formation, limb rotation, and proximal-distal axis establishment are all regulated by Wnt/PCP signaling gradients, explaining the mesomelic (mid-segment) predominance of limb shortening.

Protein Dysfunction

WNT5A is a secreted, lipid-modified signaling glycoprotein. Disease variants cluster on a modeled protein surface implicated in receptor/co-receptor engagement, consistent with altered protein-protein interaction rather than global misfolding or complete loss of secretion.

Tissue Damage / Organ-Level Mechanism

No classical oxidative-stress, ischemic, or fibrotic tissue-injury mechanism; pathology is developmental/morphogenetic rather than degenerative — abnormal patterning is established prenatally and is largely static postnatally (apart from progressive scoliosis in some).

Comparative Genotype-Mechanism Note

This is a key mechanistic distinction curators should capture: WNT5A (DRS1) variants act through the ligand with a hypomorphic/altered-signaling effect, while DVL1/DVL3 (DRS2/DRS3) variants act through downstream truncated adaptor proteins with a putative gain-of-function effect — both converging on the same non-canonical Wnt/PCP pathway but via mechanistically distinct routes, which may explain phenotypic differences (e.g., osteosclerosis/increased bone density specifically associated with DVL1, cardiac defects more frequent with DVL3) (GeneReviews NBK268648; PMC10120075).

Craniofacial-Specific Mechanism

In mandibular development, abnormal WNT5A signaling has been shown to specifically cause mandibular hypoplasia through effects on neural-crest-derived skeletal precursors (Hosseini-Farahabadi et al. 2017, J Dent Res). Conditional mouse loss- vs. gain-of-function Wnt5a alleles produce distinct, sometimes opposite craniofacial phenotypes (loss-of-function: midface hypoplasia, hypertelorism trend; gain-of-function: macrocephaly, shortened hard palate, micrognathia), mirroring the phenotypic heterogeneity seen clinically across Robinow syndrome subtypes (JBMR Plus 2024; PMC12330612, 2025).

Molecular Profiling / Omics

No large-scale transcriptomic, proteomic, metabolomic, or single-cell dataset specific to human WNT5A-Robinow syndrome tissue was identified; mechanistic insight instead derives from model-organism functional assays (zebrafish, Xenopus, chicken, Drosophila, mouse knock-in) rather than human -omics profiling — an important evidentiary caveat for curation (favor evidence_source: MODEL_ORGANISM/IN_VITRO for most mechanistic claims, HUMAN_CLINICAL only for phenotype/variant description).

Suggested GO biological process terms: GO:0035567 (non-canonical Wnt signaling pathway), GO:0060071 (PCP pathway), GO:0001501 (skeletal system development), GO:0060349 (bone morphogenesis). Suggested CL cell type terms: CL:0000138 (chondrocyte), CL:0000058 (chondroblast).

7. Anatomical Structures Affected

Organ level (primary): Skeletal system (long bones — mesomelic segments; axial skeleton — vertebrae), craniofacial skeleton, external genitalia. Secondary: cardiovascular system (minority with structural heart defects), renal system (minority), dentition.

Body systems: Skeletal, craniofacial, genitourinary, and (variably) cardiovascular and renal systems — UBERON: limb (UBERON:0002101), forearm/mesomelic segment, vertebral column (UBERON:0001130), mandible (UBERON:0000926), external genitalia (UBERON:0000474), heart (UBERON:0000948), kidney (UBERON:0002113).

Tissue/cell level: Growth-plate cartilage (chondrocytes, CL:0000138) is the principal affected tissue — polarity/columnar organization defects there directly underlie the limb-shortening phenotype. Craniofacial neural-crest-derived skeletal precursors are also implicated (Hosseini-Farahabadi 2017).

Subcellular: WNT5A is a secreted glycoprotein (extracellular space, GO:0005615); receptor complex assembly occurs at the plasma membrane; downstream Disheveled (DVL1) acts in the cytoplasm as a scaffolding adaptor (GO:0005737).

Localization/laterality: Skeletal and craniofacial involvement is generally bilateral/symmetric; mesomelic shortening classically affects forearms more than legs.

8. Temporal Development

Onset: Congenital — features (mesomelic shortening, facial gestalt) are often visible on prenatal ultrasound by ~20 weeks gestation and are present at birth (GeneReviews NBK268648).

Onset pattern: Present from birth (not acute/insidious in the acquired-disease sense).

Progression/course: Largely stable/non-progressive developmental phenotype. The characteristic "fetal facies" gestalt is most pronounced in infancy and becomes less distinctive with age. Scoliosis (when hemivertebrae are present) can be progressive through growth and requires surveillance. Short stature persists into adulthood (typically ≤ −2 SD).

Disease duration: Chronic, lifelong condition; not self-limited.

Remission patterns: Not applicable (structural/developmental disorder, not a relapsing-remitting disease).

Critical periods: Prenatal skeletal and craniofacial morphogenesis (embryonic/fetal limb bud and branchial arch development) is the critical window during which WNT5A signaling perturbation produces the phenotype; postnatal management is chiefly supportive/corrective rather than preventive of primary pathology.

9. Inheritance and Population

Epidemiology: Robinow syndrome overall is very rare; approximately 200 cases have been reported cumulatively across dominant and recessive forms. For the dominant form specifically, Orphanet lists ~100 cases reported, prevalence <1/1,000,000, equal male:female ratio, with cases described from the USA, Arab countries, Turkey, Czech Republic/Slovakia, the Indian subcontinent, and Brazil (Orphanet ORPHA:3107). Fewer than 80 dominant-Robinow families total have been reported in the literature across all three known dominant genes (~8 WNT5A probands, ~18 DVL1, ~7 DVL3, per GeneReviews) (GeneReviews NBK268648).

Inheritance pattern: Autosomal dominant. Approximately 50% of cases are de novo; the remainder are inherited from an affected (often mildly expressing) parent, consistent with Robinow's original multi-generation family.

Penetrance: Appears high/complete for the core skeletal-craniofacial phenotype, though expressivity is markedly variable — severity differs even among relatives sharing the identical WNT5A variant (per Robinow's original family report).

Genetic anticipation: Not reported/established for WNT5A-Robinow syndrome (this is not a repeat-expansion disorder).

Germline mosaicism: Considered a theoretical possibility for recurrence in unaffected parents of a de novo proband; GeneReviews estimates sibling recurrence risk at roughly ~1% in such cases, reflecting this low but non-zero mosaicism risk.

Founder effects/consanguinity: Not documented for the dominant WNT5A form (consanguinity and founder effects are more relevant to the recessive ROR2/NXN forms, which are enriched in certain consanguineous populations, e.g., Turkish, Middle Eastern, Omani cohorts — relevant differential/background context, not DRS1 itself).

Carrier frequency: Not applicable in the traditional sense (dominant disorder); population allele frequency of pathogenic WNT5A missense variants in gnomAD is expected to be essentially absent/private, consistent with a rare, largely de novo dominant disorder (specific gnomAD frequency data not retrieved in this search pass).

Population demographics: No specific ethnic enrichment established for WNT5A-associated DRS1; case reports span multiple continents/ethnicities as above. Sex ratio approximately 1:1.

10. Diagnostics

Diagnostic criteria (GeneReviews): Diagnosis established by (1) typical clinical findings (fetal facies, mesomelic limb shortening, genital hypoplasia ± vertebral/renal anomalies) and/or (2) identification of a heterozygous pathogenic variant in DVL1, DVL3, or WNT5A by molecular genetic testing (GeneReviews NBK268648).

Molecular testing strategy: 1. First-tier: sequence analysis of DVL1 and DVL3 (the more commonly implicated genes), concurrently or sequentially 2. Reflex: WNT5A sequence analysis if DVL1/DVL3 negative 3. Alternative: multigene skeletal-dysplasia panel, or exome/genome sequencing 4. Detection rate: sequence analysis identifies >99% of pathogenic DVL1/DVL3 variants; deletion/duplication analysis is low-yield given the presumed gain-of-function mechanism for those genes.

Imaging/clinical tests: - Skeletal radiographs (mesomelic long-bone shortening, hemivertebrae, brachydactyly) - Prenatal ultrasound (limb shortening, facial features detectable ~20 weeks) - Echocardiography (screen for congenital heart defects) - Renal ultrasound (screen for renal anomalies) - Dental/orthodontic and craniofacial evaluation - Hearing assessment - Developmental assessment

Genetic testing modalities: Single-gene sequencing (WNT5A), multigene panel (WNT5A + DVL1 + DVL3 + ROR2 + NXN + FZD2), or exome/genome sequencing. Chromosomal microarray/karyotype not diagnostically useful (point-mutation disorder). Prenatal molecular testing available once a familial variant is known.

Differential diagnosis:

Screening: No population-based newborn screening exists (too rare); cascade family testing recommended once a familial variant is identified, given variable expressivity that may mean a "carrier" parent is only subtly affected.

11. Outcome/Prognosis

Survival/mortality: Life expectancy is generally considered normal, in marked contrast to some skeletal dysplasias, except when significant congenital cardiac defects are present — cardiac defects are explicitly described as "a major cause of morbidity and mortality" in ADRS when they occur (GeneReviews NBK268648).

Morbidity/function: Main long-term morbidity drivers are orthopedic (progressive scoliosis, limb-length/short stature issues), dental/orthodontic burden, and (for a minority) renal or cardiac complications. Cognitive function is typically normal, an important prognostic distinction from the recessive ROR2 form, which carries higher rates of developmental delay.

Complications: Progressive scoliosis from hemivertebrae, malocclusion requiring extensive orthodontic/surgical correction, cryptorchidism, hearing loss (more DVL1-associated), and — when present — structural cardiac lesions requiring surgical correction.

Recovery/prognostic factors: Prognosis correlates with which organ systems are involved (particularly cardiac and renal) more than with limb/facial severity per se; genotype (WNT5A vs. DVL1 vs. DVL3) is associated with somewhat different complication profiles (see Section 6/10).

Pregnancy: "Pregnancy in affected women appears to be generally uncomplicated," though cesarean delivery may be needed for abnormal fetal presentation or cephalopelvic disproportion related to maternal skeletal anatomy (GeneReviews NBK268648).

12. Treatment

There is no disease-modifying/curative therapy; management is multidisciplinary and manifestation-directed.

Pharmacotherapy: - Recombinant human growth hormone (rhGH) has been used in children with Robinow syndrome, particularly with documented growth hormone deficiency, with reported significant increase in growth velocity (case example: 0.7 U/kg/week starting at age 4, height rising from <1st to 44th percentile) (Robinow syndrome and its response to growth hormone treatment, PMID:36917807; PMID:10417975). Suggested NCIT term: NCIT:C15986 (Pharmacotherapy) with a specific growth-hormone therapeutic agent. - Hormonal therapy (hCG/testosterone) for micropenis in affected males — NCIT:C15986.

Surgical/Interventional: - Craniofacial team surgical correction of cleft lip/palate — NCIT:C15329 (Surgical Procedure) - Orthopedic surgery for severe scoliosis (hemivertebral/costal anomalies), syndactyly — NCIT:C16186 (Orthopedic Surgical Procedure) - Orchidopexy for cryptorchidism; urological correction for anomalous penile insertion — NCIT:C15329 - Standard cardiothoracic surgical management for congenital heart defects when present

Supportive/rehabilitative: - Orthodontic treatment for malocclusion/crowding — NCIT:C15302-adjacent dental care code, or general therapeutic procedure - Bracing, casting, physical therapy as first-line for musculoskeletal issues before surgery is considered — NCIT:C15302 (Physical Therapy) - Hearing intervention (amplification) for documented hearing loss - Genetic counseling — NCIT:C15240

Experimental/advanced therapeutics: No gene therapy, RNA-based therapy, or targeted molecular therapy specific to WNT5A-Robinow syndrome was identified in the literature searched; this remains a management-only (not mechanism-correcting) treatment landscape at present. No relevant ClinicalTrials.gov interventional trials specific to DRS1 were surfaced in this search.

Treatment strategy/surveillance schedule (per GeneReviews): - Craniofacial/dental evaluation every 6–12 months - Developmental assessment at each visit through childhood/adolescence - Cardiac and renal monitoring if abnormalities identified at baseline - Regular head-circumference measurement in infancy/childhood

13. Prevention

Primary prevention: Not applicable in the classic sense (monogenic disorder); the only "primary prevention" avenue is reproductive genetic counseling and prenatal/preimplantation genetic testing once a familial WNT5A variant is identified.

Secondary prevention (early detection): Prenatal ultrasound can detect the mesomelic limb-shortening and craniofacial phenotype from ~20 weeks gestation in at-risk pregnancies, enabling early postnatal multidisciplinary planning (GeneReviews NBK268648).

Tertiary prevention: Scheduled surveillance (craniofacial, cardiac, renal, developmental, scoliosis) is aimed at preventing/mitigating secondary complications rather than the primary skeletal dysplasia itself.

Genetic counseling: Central to prevention/family planning — 50% recurrence risk to offspring of an affected parent; ~1% empiric recurrence risk to siblings of a de novo proband (accounting for possible parental germline mosaicism); prenatal and preimplantation genetic testing available once the familial variant is known.

Screening: No population-level screening program exists given the extreme rarity; family cascade testing is the operative screening paradigm.

Immunization/infectious prophylaxis: Not applicable — non-infectious etiology.

14. Other Species / Natural Disease

Taxonomy of affected species used in models: Danio rerio (zebrafish, NCBITaxon:7955), Xenopus laevis (NCBITaxon:8355), Gallus gallus (chicken, NCBITaxon:9031), Drosophila melanogaster (NCBITaxon:7227), Mus musculus (mouse, NCBITaxon:10090).

Naturally occurring disease in other species: A DVL1-related Robinow syndrome phenotype has been documented in chicken (Gallus gallus), catalogued in OMIA as OMIA:002654-9031 (OMIA) — this is the DVL1 (DRS2) ortholog rather than WNT5A/DRS1 specifically, but is relevant comparative context within the same gene family/pathway. No naturally occurring WNT5A-specific Robinow phenotype in a companion-animal or veterinary population was identified in this search (contrast with the well-documented naturally occurring ROR2-related "brachycephalic/mesomelic dwarfism" in some cattle and dog breeds, which is a separate ROR2-pathway veterinary correlate worth checking OMIA directly if curating comparative content).

Orthologous gene: WNT5A is highly conserved across vertebrates; mouse Wnt5a, zebrafish wnt5b (a paralog performing an analogous non-canonical signaling role), chicken WNT5A, and Xenopus Wnt5a orthologs are all used experimentally (see Section 15).

Comparative pathology: Across species, loss or dysregulation of Wnt5a/non-canonical Wnt signaling produces convergent phenotypes of shortened/disorganized body axis, disrupted convergent-extension gastrulation movements, and craniofacial/limb skeletal patterning defects — indicating strong evolutionary conservation of the underlying PCP mechanism (see zebrafish pipetail mutant, PMC1299299).

Zoonotic potential: Not applicable — this is a developmental/genetic disorder, not a transmissible disease.

15. Model Organisms

Model limitations: No model fully recapitulates the complete human multi-organ phenotype (craniofacial + skeletal + genital + cardiac + renal) simultaneously; mouse germline Wnt5a nulls are non-viable, limiting study of postnatal/adult phenotype, which is why knock-in (patient-variant) and conditional models have become the preferred tools for modeling the milder, viable human dominant phenotype. Non-mammalian models (zebrafish, Xenopus, chicken, Drosophila) are valuable for rapid functional variant classification (gain vs. loss of function) but cannot model human-specific structures (dentition, genital anatomy) or long-term skeletal growth-plate biology as faithfully as mammalian systems.

Applications: These models collectively support (1) variant functional classification (pathogenic missense vs. benign), (2) mechanistic dissection of canonical-vs-non-canonical Wnt pathway involvement, (3) chondrocyte planar-polarity read-outs as a cellular biomarker of pathogenicity, and (4) comparative dissection of WNT5A (ligand-level, hypomorphic) versus DVL1/DVL3 (adaptor-level, gain-of-function) disease mechanisms within the same overall pathway.

Summary of Key Ontology Term Suggestions for KB Curation

Notable Evidence Gaps for Curators

1. DRS1 (WNT5A) is under-represented in recent mechanistic literature relative to DRS2/DRS3 (DVL1/DVL3) — most 2023–2025 primary mechanistic papers found in this search (Drosophila, chicken, zebrafish DVL work) concern DVL1/DVL3, not WNT5A directly; WNT5A mechanistic evidence is mostly from Person et al. 2010 plus the C83S knock-in mouse line (2019, 2025).
2. No human transcriptomic/proteomic/single-cell dataset specific to WNT5A-Robinow patient tissue was located — mechanistic claims should be sourced as MODEL_ORGANISM/IN_VITRO, not HUMAN_CLINICAL.
3. Exact PMID for the original 1969 Robinow, Silverman & Smith description was not resolved via search (pre-PubMed-indexing era article); if required for citation, retrieve directly from Am J Dis Child 1969;117:645–651 via a library/DOI lookup rather than PubMed search.
4. No NCT-registered interventional trial specific to DRS1/WNT5A-Robinow syndrome was identified.

Sources: OMIM #180700 · OMIM #616331 · OMIM #616894 · GeneReviews — Autosomal Dominant Robinow Syndrome (NBK268648) · GeneReviews — ROR2-Related Robinow Syndrome (NBK1240) · Orphanet ORPHA:3107 · Person et al. 2010, Dev Dyn, PMID:19918918 · White et al. 2015, AJHG, PMID:25817016 · Roifman et al. 2015, PMID:25817014 · Human Molecular Genetics 2019 — WNT5A-C83S dominant interference · PMC12776500 — Wnt5a-C83S knock-in chondrocyte polarity 2025 · PMC10120075 — DVL1 mechanistic studies in Drosophila/chicken · JBMR Plus 2024 — Wnt5a gain/loss-of-function craniofacial bone · PMC12330612 · Hosseini-Farahabadi et al. 2017, J Dent Res · Robinow syndrome and growth hormone treatment, PMID:36917807 · PMID:10417975 · OMIA:002654-9031 (chicken DVL1-related Robinow) · Disease Ontology DOID:0060766

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.